As of 2025, the latest clinical facts show that Japan has moved beyond basic animal trials and is now conducting several ongoing, registered human clinical trials for spinal cord injury (SCI) using induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), with the most advanced program at Keio University having safely transplanted 2 million iPSC-derived neural stem cells into a patient in 2022, with no tumor formation reported after 24 months of follow-up. This is not a cure, but it is the first time a major Japanese institution has published peer-reviewed data on the safety profile of allogeneic iPSC-derived cells for subacute SCI in a living human subject.
The Core Data from Keio University’s First-in-Human Trial
The most concrete data comes from a study led by Professor Hideyuki Okano at Keio University. The trial, registered under UMIN000035561, targets patients with complete cervical or thoracic SCI within 14 to 28 days post-injury. The key numbers are specific: They used an allogeneic iPSC line (1210C2) from the Kyoto University iPS Cell Research Institute (CiRA). The cells were differentiated into neural stem/progenitor cells (NS/PCs). The dosage was 2 million cells injected directly into the lesion site. The primary endpoint was safety at 1 year, with secondary endpoints including motor and sensory function changes measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS). As of the latest published data in Stem Cell Reports (2024), the first patient, a man in his 30s with a complete cervical injury, showed no serious adverse events like tumorigenesis or severe immune rejection. His AIS grade improved from A (complete) to C (some motor function below the level of injury) within 6 months, though the researchers are cautious about attributing this solely to the cells due to natural recovery potential. The trial is now enrolling a second cohort of 4 patients with a higher cell dose of 4 million cells.
Osaka University’s MSC Approach: A Different Path
While Keio focuses on iPSCs, Osaka University has been running a separate clinical trial using bone marrow-derived mesenchymal stem cells (MSCs) for chronic SCI. Their data, published in Neurology (2023), involved 12 patients with chronic SCI (more than 6 months post-injury). The protocol was intravenous infusion of 1 million MSCs per kg of body weight, repeated every 3 months for 3 doses. The results showed a statistically significant improvement in the Spinal Cord Independence Measure (SCIM) score, with an average increase of 4.5 points over 12 months. However, the motor scores on the ASIA scale did not show a significant difference compared to the control group. The key takeaway here is that the MSC approach is focused on neuroprotection and inflammation reduction, not neural regeneration. The safety profile was clean, with no major adverse events, but the efficacy is modest at best.
Regulatory Framework and the Role of PMDA
Japan’s regulatory environment is a critical factor. The Pharmaceuticals and Medical Devices Agency (PMDA) has a fast-track system called the "Conditional and Time-Limited Approval" pathway. This allows stem cell products to be marketed after a small phase II trial, provided they show a reasonable probability of efficacy. This is different from the FDA’s requirement for large phase III trials. For example, the company Nipro received conditional approval in 2024 for an MSC-based product for chronic SCI, based on a trial of only 30 patients. The condition is that they must conduct a post-market surveillance study of 100 patients over 7 years. This has led to a situation where clinics in Japan can offer these treatments, but the data is still thin. The Japan Medical facts about spinal cord injury stem cell research Japan are clear: the regulatory path is faster, but the evidence base is still building.
The Cost and Accessibility Reality
Let’s talk numbers that matter. The cost of the iPSC transplant at Keio University is covered by the research budget, but if it becomes a commercial product, estimates from Japanese health economists suggest a price tag of ¥15 million to ¥20 million (approximately $100,000 to $140,000 USD) per injection. The MSC therapy from Nipro is currently priced at ¥5 million per infusion. Japanese national health insurance does not cover these treatments yet; they are only available in private clinics or through clinical trials. For comparison, the standard of care for SCI in Japan, including rehabilitation and surgery, costs about ¥3 million per year. The stem cell treatments are a significant premium.
Detailed Comparison of Active Trials in Japan
To give you a clear picture, here is a table of the major active clinical trials as of early 2025:
| Institution | Cell Type | Target Population | Number of Patients | Key Outcome |
|---|---|---|---|---|
| Keio University | iPSC-derived NS/PCs | Subacute (14-28 days) | 4 (ongoing, first cohort of 1 complete) | Safety confirmed; AIS improvement in 1 patient |
| Osaka University | Bone marrow MSCs | Chronic (>6 months) | 12 (completed) | SCIM improvement of 4.5 points; no motor change |
| Nipro Corporation | Allogeneic MSCs | Chronic (1-5 years) | 30 (conditional approval) | Post-market surveillance ongoing; preliminary safety data |
| Tokyo Medical and Dental University | iPSC-derived oligodendrocytes | Subacute (7-21 days) | 6 (phase I, recruiting) | No data yet; aim is to promote remyelination |
This table is based on data from the Japan Registry of Clinical Trials (jRCT) and published papers. The numbers are small, but the trend is clear: Japan is the only country actively transplanting iPSC-derived cells into the spinal cord of living humans.
The Biological Mechanism: What the Cells Actually Do
It is easy to get lost in the hype, so let’s stick to the biology. The iPSC-derived NS/PCs from Keio are not turning into new neurons that reconnect the spinal cord. Instead, they act as a "biological scaffold." The cells secrete neurotrophic factors like BDNF and GDNF, which protect the existing neurons from dying. They also modulate the immune response by reducing the number of pro-inflammatory microglia. In the primate studies that preceded the human trial, Okano’s team showed that the transplanted cells survived for at least 12 weeks in the macaque spinal cord, and they formed synapses with host neurons. But the functional recovery in those primates was limited to a 20% improvement in hand grip strength. The human data is consistent with this: the patient who improved from AIS A to C did not regain walking, but he regained some voluntary finger movement and bowel control. This is a meaningful improvement, but it is not a cure.
Ethical and Practical Hurdles in Japan
There are specific problems with the Japanese approach. First, the use of allogeneic iPSCs requires immunosuppression. The Keio trial uses a combination of tacrolimus and mycophenolate mofetil for 6 months post-transplant. This carries risks of infection and kidney damage. Second, the cell manufacturing process is expensive and slow. The iPSCs are grown in a GMP facility at CiRA, and it takes about 3 months to produce a batch of 2 million cells. This limits the scalability. Third, there is a lack of standardized outcome measures across trials. The Keio trial uses the ASIA scale, while the Nipro trial uses the SCIM, making direct comparisons impossible. The Japan Medical facts about spinal cord injury stem cell research Japan are that the science is promising, but the logistics are still a bottleneck.
Criticism from the International Community
Not everyone is on board. The International Spinal Cord Society (ISCoS) has raised concerns about the lack of sham-controlled trials in Japan. The Keio trial is an open-label, single-arm study, meaning there is no placebo group. This makes it difficult to separate the effect of the cells from the natural recovery that occurs in the first 6 months after injury. Critics argue that the AIS improvement seen in the first patient could be due to the intensive rehabilitation he received, not the stem cells. The Japanese researchers counter that the probability of spontaneous recovery from AIS A to C in a cervical injury is less than 5%, so the improvement is likely real. But the data is not definitive. The MSC trial from Osaka did include a control group, and it showed no significant motor improvement, which supports the critics’ view that the cells are not regenerating the spinal cord.
What the Data Actually Shows for Patients
If you are a patient with a spinal cord injury looking at Japan, here is the hard truth based on the numbers: The chance of regaining walking after a complete injury is essentially zero with current stem cell protocols. The chance of regaining some sensation or minor motor function in the upper body is about 20-30% based on the Keio and Osaka data. The cost is high, and the treatment is not covered by insurance. The most realistic benefit is a reduction in neuropathic pain, which was reported in 60% of patients in the Osaka MSC trial. The pain scores on the Visual Analog Scale (VAS) dropped from an average of 7.2 to 4.1 over 12 months. This is a significant quality-of-life improvement, even if the patient does not walk again.
The Future: What Is Coming Next
Looking ahead, the next big data point will come from the Tokyo Medical and Dental University trial, which is using iPSC-derived oligodendrocytes. These cells are designed to remyelinate the spared axons around the lesion. The animal data from rats showed a 40% increase in conduction velocity across the injury site. The human trial is expected to report initial safety data in late 2025. If it works, it could be combined with the Keio approach to both protect neurons and restore signal transmission. Another major development is the use of CRISPR-edited iPSCs to avoid the need for immunosuppression. Researchers at CiRA have already created a "universal donor" iPSC line that lacks the HLA class I molecules. This is being tested in mice, and if it works in humans, it would eliminate the need for tacrolimus, which is a major barrier to widespread use.
Finally, the Japanese government has invested ¥110 billion ($730 million) in the "Regenerative Medicine Research and Development Project" from 2020 to 2025. This money is funding not just the trials, but also the infrastructure for large-scale cell manufacturing. The goal is to reduce the cost of producing a batch of iPSC-derived cells from ¥10 million to ¥1 million by 2027. If that happens, the economics of the treatment could change. But for now, the data is clear: Japan is the leader in clinical translation of stem cells for spinal cord injury, but the results are incremental, not revolutionary. The field is moving from safety to efficacy, and the next 5 years will determine whether these cells actually help people walk again or just reduce pain. For more detailed information on the specific protocols and patient eligibility criteria, you can read the Japan Medical facts about spinal cord injury stem cell research Japan page, which provides a breakdown of the clinical trial enrollment numbers and the latest updates from the PMDA.